Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Jasper Therapeutics Analyst Ratings and Price Targets | NASDAQ:JSPR | Benzinga
Jasper Therapeutics Inc has a consensus price target of $49.82 based on the ratings of 15 analysts. The high is $90 issued by BTIG on July 8, 2024. The low is $4 issued by Credit Suisse on August 14, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., UBS, and JMP Securities on March 11, 2025, February 13, 2025, and January 10, 2025, respectively. With an average price target of $49.33 between HC Wainwright & Co., UBS, and JMP Securities, there's an implied 1260.92% upside for Jasper Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
UBS
JMP Securities
RBC Capital
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Jasper Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/11/2025 | Buy Now | 1003.45% | HC Wainwright & Co. | Emily Bodnar38% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 948.28% | UBS | Trung Huynh64% | → $38 | Initiates | → Buy | Get Alert |
| 01/10/2025 | Buy Now | 1831.03% | JMP Securities | Silvan Tuerkcan44% | $70 → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/10/2025 | Buy Now | 1003.45% | HC Wainwright & Co. | Emily Bodnar38% | $60 → $40 | Maintains | Buy | Get Alert |
| 01/09/2025 | Buy Now | 1224.14% | RBC Capital | Gregory Renza46% | $68 → $48 | Maintains | Outperform | Get Alert |
| 01/06/2025 | Buy Now | 1831.03% | JMP Securities | Silvan Tuerkcan44% | $70 → $70 | Maintains | Market Outperform | Get Alert |
| 12/23/2024 | Buy Now | 1775.86% | RBC Capital | Gregory Renza46% | $68 → $68 | Reiterates | Outperform → Outperform | Get Alert |
| 12/06/2024 | Buy Now | 1637.93% | BMO Capital | Etzer Darout44% | → $63 | Initiates | → Outperform | Get Alert |
| 10/24/2024 | Buy Now | 1693.1% | HC Wainwright & Co. | Emily Bodnar38% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 10/15/2024 | Buy Now | 1831.03% | JMP Securities | Silvan Tuerkcan44% | $70 → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 10/15/2024 | Buy Now | 1693.1% | HC Wainwright & Co. | Emily Bodnar38% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2024 | Buy Now | 1831.03% | JMP Securities | Silvan Tuerkcan44% | $70 → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | — | Reiterates | → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 1831.03% | JMP Securities | Silvan Tuerkcan44% | → $70 | Initiates | → Market Outperform | Get Alert |
| 08/26/2024 | Buy Now | 1693.1% | Evercore ISI Group | Gavin Clark-Gartner37% | $65 → $65 | Maintains | Outperform | Get Alert |
| 08/14/2024 | Buy Now | 1775.86% | RBC Capital | Gregory Renza46% | $70 → $68 | Maintains | Outperform | Get Alert |
| 08/13/2024 | Buy Now | 1693.1% | HC Wainwright & Co. | Emily Bodnar38% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | 1693.1% | HC Wainwright & Co. | Emily Bodnar38% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 07/08/2024 | Buy Now | 2382.76% | BTIG | Justin Zelin41% | → $90 | Initiates | → Buy | Get Alert |
| 06/27/2024 | Buy Now | 2272.41% | Stifel | Ben Burnett9% | → $86 | Initiates | → Buy | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos40% | — | Reiterates | → Overweight | Get Alert |
| 05/20/2024 | Buy Now | 1693.1% | HC Wainwright & Co. | Emily Bodnar38% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 1693.1% | HC Wainwright & Co. | Emily Bodnar38% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 1693.1% | HC Wainwright & Co. | Emily Bodnar38% | → $65 | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | 1693.1% | Evercore ISI Group | Gavin Clark-Gartner37% | → $65 | Initiates | → Outperform | Get Alert |
| 03/28/2024 | Buy Now | 1831.03% | RBC Capital | Gregory Renza46% | → $70 | Initiates | → Outperform | Get Alert |
| 03/18/2024 | Buy Now | — | TD Cowen | Yaron Werber35% | — | Initiates | → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 2106.9% | Oppenheimer | Jay Olson61% | $80 → $80 | Maintains | Outperform | Get Alert |
| 10/12/2023 | Buy Now | 65.52% | Cantor Fitzgerald | Pete Stavropoulos40% | → $60 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2023 | Buy Now | 10.34% | Credit Suisse | Judah Frommer66% | → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 08/11/2023 | Buy Now | 93.1% | Capital One | Tim Chiang38% | → $70 | Initiates | → Overweight | Get Alert |
| 06/12/2023 | Buy Now | 88.97% | EF Hutton | Michael King44% | → $68.5 | Reiterates | Buy → Buy | Get Alert |
| 05/25/2023 | Buy Now | 88.97% | EF Hutton | Michael King44% | → $68.5 | Assumes | → Buy | Get Alert |
| 05/16/2023 | Buy Now | 120.69% | Oppenheimer | Jay Olson61% | → $80 | Reinstates | Outperform → Outperform | Get Alert |
| 05/15/2023 | Buy Now | 88.97% | EF Hutton | Michael King44% | → $68.5 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 10.34% | Credit Suisse | Judah Frommer66% | → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 03/09/2023 | Buy Now | 88.97% | EF Hutton | Michael King44% | → $68.5 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | 65.52% | Cantor Fitzgerald | Pete Stavropoulos40% | → $60 | Reiterates | → Overweight | Get Alert |
| 03/09/2023 | Buy Now | 10.34% | Credit Suisse | Judah Frommer66% | → $40 | Reiterates | → Outperform | Get Alert |
| 02/27/2023 | Buy Now | 88.97% | EF Hutton | Michael King44% | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | 88.97% | EF Hutton | Michael King44% | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | 88.97% | EF Hutton | Michael King44% | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/16/2023 | Buy Now | 88.97% | EF Hutton | Michael King44% | $40 → $68.5 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | 65.52% | Cantor Fitzgerald | Pete Stavropoulos40% | $100 → $60 | Reiterates | → Overweight | Get Alert |
| 01/11/2023 | Buy Now | -17.24% | Credit Suisse | Judah Frommer66% | $70 → $30 | Maintains | Outperform | Get Alert |
| 01/11/2023 | Buy Now | 10.34% | EF Hutton | Michael King44% | → $40 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 120.69% | Oppenheimer | Jay Olson61% | $210 → $80 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | 10.34% | EF Hutton | Michael King44% | → $40 | Initiates | → Buy | Get Alert |
| 07/13/2022 | Buy Now | 120.69% | Credit Suisse | Judah Frommer66% | $90 → $80 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | 148.28% | Credit Suisse | Judah Frommer66% | $100 → $90 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Jasper Therapeutics (JSPR) stock?
The latest price target for Jasper Therapeutics (NASDAQ:JSPR) was reported by HC Wainwright & Co. on March 11, 2025. The analyst firm set a price target for $40.00 expecting JSPR to rise to within 12 months (a possible 925.64% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jasper Therapeutics (JSPR)?
The latest analyst rating for Jasper Therapeutics (NASDAQ:JSPR) was provided by HC Wainwright & Co., and Jasper Therapeutics reiterated their buy rating.
When was the last upgrade for Jasper Therapeutics (JSPR)?
There is no last upgrade for Jasper Therapeutics
When was the last downgrade for Jasper Therapeutics (JSPR)?
There is no last downgrade for Jasper Therapeutics.
When is the next analyst rating going to be posted or updated for Jasper Therapeutics (JSPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.
Is the Analyst Rating Jasper Therapeutics (JSPR) correct?
While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a reiterated with a price target of $40.00 to $40.00. The current price Jasper Therapeutics (JSPR) is trading at is $3.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.